Β1 adrenergic receptor polymorphisms and heart failure: A meta-analysis on susceptibility, response to β-blocker therapy and prognosis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Liu, Wen Nan ^a,b   Fu, Kai Li ^a,b   Gao, Hai Yang ^a,b   Shang, Yuan Yuan ^a,b   Wang, Zhi Hao ^a,b   Jiang, Gui Hua ^a,b   Zhang, Yun ^a,b   Zhang, Wei ^a,b   Zhong, Ming ^a,b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCINE; METOPROLOL; SERINE;

ARTICLE; CAUCASIAN; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG RESPONSE; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOMOZYGOSITY; HUMAN; HYPERTENSION; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; META ANALYSIS; PREDICTION; PROGNOSIS; RISK FACTOR; SENSITIVITY ANALYSIS; SOUTHEAST ASIA;

ADRENERGIC BETA-ANTAGONISTS; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 84864012546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037659     Document Type: Article

References (53)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2009) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al. (2009) 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90.
3. Fang J, Mensah GA, Croft JB, Keenan NL, (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52: 428-434.
4. de Groote P, Delour P, Mouquet F, Lamblin N, Dagorn J, et al. (2007) The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J 154: 589-95.
5. Seghatol FF, Shah DJ, Diluzio S, Bello D, Johnson MR, et al. (2004) Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 93: 854-859.
6. Francis GS, Tang WH, (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145: 200-202.
7. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, et al. (2003) Marked improvement in left ventricular ejection fraction during long term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 145: 292-299.
8. Lohse MJ, (2004) Beta-adrenoceptor polymorphisms and heart failure. Trends Mol Med 10: 55-58.
9. Higgins JPT, Green S, (2011) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons. 672 p.
10. Weir BS, (1990) Genetic Data Analysis: Methods for Discrete Population Genetic Data. Sinauer Associates. 377 p.
11. Higgins JPT, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
12. Wang L, Lu L, Zhang F, Chen Q, Shen W, (2010) Polymorphisms of beta-adrenoceptor and natriuretic peptide receptor genes influence the susceptibility to and the severity of idiopathic dilated cardiomyopathy in a Chinese cohort. J Card Fail 16: 36-44.
13. Paczkowska A, Szperl M, Małek Ł, Mazurkiewicz Ł, Skóra E, et al. (2009) Polymorphisms of the beta-1 and beta-2 adrenergic receptors in Polish patients with idiopathic dilated cardiomyopathy. Kardiol Pol 67: 235-241.
14. Woodiwiss AJ, Badenhorst D, Sliwa K, Brooksbank R, Essop R, et al. (2008) Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry. Cardiovasc J Afr 19: 188-193.
15. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, et al. (2008) Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 102: 726-732.
16. Yu WP, Lou M, Deng B, Song HM, Wang HB, (2006) Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 34: 776-780.
17. Nonen S, Okamoto H, Akino M, Matsui Y, Fujio Y, (2005) No positive association between adrenergic receptor variants of alpha- 2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population. Br J Clin Pharmacol 60: 414-417.
18. Covolo L, Gelatti U, Metra M, Nodari S, Piccichè A, et al. (2004) Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study. Eur Heart J 25: 1534-1541.
19. Magnusson Y, Levin MC, Eggertsen R, Nyström E, Mobini R, et al. (2005) Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 78: 221-231.
20. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB, (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135-1142.
21. Iwai C, Akita H, Shiga N, Takai E, Miyamoto Y, et al. (2002) Suppressive effect of the Gly389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 66: 723-728.
22. Forleo C, Sorrentino S, Guida P, Romito R, de Tommasi E, et al. (2007) Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown) 8: 589-595.
23. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, et al. (1999) Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol 31: 1025-1032.
24. Fragoso JM, Rodríguez-Pérez JM, González J, Cruz D, Pérez-Méndez O, et al. (2006) Beta1-adrenergic receptor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol 80: 279-282.
25. Podlowski S, Wenzel K, Luther HP, Müller J, Bramlage P, et al. (2000) Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med (Berl) 78: 87-93.
26. Metra M, Covolo L, Pezzali N, Zacà V, Bugatti S, et al. (2010) Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 24: 49-60.
27. Chen L, Meyers D, Javorsky G, Burstow D, Lolekha P, et al. (2007) Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet Genomics 17: 941-949.
28. Luo M, Bi Y, Xu YX, (2007) Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure. Chin Med J (Engl) 120: 1720-1723.
29. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, et al. (2006) A polymorphism within a conserved beta (1)- adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103: 11288-11293.
30. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, et al. (2005) Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 15: 227-234.
31. de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, et al. (2005) Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 15: 137-142.
32. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, et al. (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9: 1300-1305.
33. Petersen M, Andersen JT, Hjelvang BR, Broedbaek K, Afzal S, et al. (2011) Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol 71: 556-565.
34. Leineweber K, Frey UH, Tenderich G, Toliat MR, Zittermann A, et al. (2010) The Arg16Gly-β (2)-adrenoceptor single nucleotide polymorphism: exercise capacity and survival in patients with end-stage heart failure. Naunyn Schmiedebergs Arch Pharmacol 382: 357-365.
35. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, et al. (2009) Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 54: 432-444.
36. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, et al. (2003) An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5: 463-468.
37. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, et al. (2004) Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. Am J Med 117: 451-458.
38. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, et al. (2007) Relation of beta (2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 99: 250-255.
39. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y, (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277: 30429-30435.
40. Mason DA, Moore JD, Green SA, Liggett SB, (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J Biol Chem 274: 12670-12674.
41. Rathz DA, Gregory KN, Fang Y, Brown KM, Liggett SB, (2003) Hierarchy of polymorphic variation and desensitization permutations relative to beta (1)- and beta (2)-adrenergic receptor signaling. J Biol Chem 278: 10784-10789.
42. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, et al. (2003) β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9: 1300-1305.
43. Liggett SB, (2010) Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart Fail Clin 6: 27-33.
44. Jin B, Ge-Shang QZ, Li Y, Shen W, Shi HM, et al. (2011) A meta-analysis of β1-adrenergic receptor gene polymorphisms in idiopathic dilated cardiomyopathy. Mol Biol Rep 39: 563-567.
45. Li YJ, Li N, Yang L, Li YW, Ding X, et al. (2011) Polymorphisms of Arg389Gly of β1-adrebergic receptor gene and essential hypertension risk: a meta-analysis. Zhonghua Yi Xue Za Zhi 91: 3115-3119.
46. McLean RC, Hirsch GA, Becker LC, Kasch-Semenza L, Gerstenblith G,et al. Polymorphisms of the beta adrenergic receptor predict left ventricular remodeling following acute myocardial infarction. Cardiovasc Drugs Ther 25: 251-258.
47. Djoussé L, Driver JA, Gaziano JM, (2009) Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 302: 394-400.
48. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, et al. (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74: 372-379.
49. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, et al. (2001) Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104: 2194-2199.
50. Jensen BC, O'Connell TD, Simpson PC, (2010) Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 51: 518-528.
51. Brodde OE, (1991) Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203-242.
52. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, et al. (2011) Influence of global region on outcomes in heart failure β-blocker trials. J Am Coll Cardiol 58: 915-922.
53. Muthumala A, Drenos F, Elliott PM, Humphries SE, (2008) Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 10: 3-13.